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Abstract
Muscular dystrophies are a diverse group of inherited muscle disorders with a wide
range of clinical manifestations from a severe form with early onset and early death to
adult forms with later onset and minimal clinical manifestation that do not affect
life-span. Overlapping clinical symptoms and the multitude of genes that need to be
analyzed for an accurate characterization make the diagnosis hard. In next-generation
sequencing era, a lot of used assay in molecular diagnostics must be taken into consid-
eration formuscular dystrophy diagnosis. However, formore accurate diagnosis, muscle
protein expressions analysis may have prognostic value. In this chapter, we present the
most important clinical and laboratory findings in the most common forms of muscular
dystrophies and molecular diagnostic approaches for a more accurate diagnosis.
Keywords: muscular dystrophy, multiplex Western blot, immunofluorescence,
MLPA, hrMCA, dystrophin, calpain 3, DMD gene, CAPN3, genetic diagnosis
1. Introduction
Muscular dystrophies (MD) are an inherited group of genetic disorders clinically
characterized by progressive muscular weakness and wasting [1] and reduced skeletal
muscle mass until their destruction due to a primary defect in the muscle cell. To date,
there are knownmore than 30 different forms of MDwith specific signs, symptoms,
and genetic basis but sharing common histological features like variation in fiber shape
and size and the presence of degeneration and regenerating fibers and connective tissue
proliferation [2]. The diseases are distinguished from one another by the age of onset,
muscles affected, as well as rate of disease progression [3]. While for some forms of
MD, the initial symptoms manifested begin with childhood and have a rapid progres-
sion of muscle weakness causing the death of the patients around the age of 20 years,
the other forms debut later in adulthood [4, 5] and have a slow rate of progression and
an almost normal lifetime [6, 7]. Also, heart disease andmental retardation accompany
some types of MD [8, 9], suggesting a different pathogenesis of the disease. It also
found that there are subtypes of MD that share similar clinical manifestations and
different genetic defects with similar clinical manifestation [10, 11].
However, the progress made in the past 33 years, since the first protein involved
in a type of muscular dystrophy was discovered, leads to identify a large number of
the genes as well as novel proteins involved in these muscle disorders [12].
For a rapid and an accurate diagnosis improvement in analysis, methods have
become a necessity. The combination of clinical signs with muscle histopathology
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and protein and genetic analyses becomes the diagnostic gold standard for these
disorders. Nevertheless, for many patients with yet unidentified muscular dystro-
phy, the diagnosis continues to be challenging.
In this book chapter, we draw attention on clinical manifestation and the most
important laboratory investigations such us muscle histopathology, protein analy-
sis, and genetic tests that can help in distinguishing between different forms of
muscular dystrophy and could lead to an accurate diagnosis.
2. A general approach to the diagnosis of muscular dystrophy
The complexity and similarity of clinical manifestation of these conditions rep-
resent a challenge for getting an accurate diagnosis for patients. A complete diag-
nosis involved clinical examination and patient’s medical history, blood tests
(creatine kinase and serum transaminase levels), electromyography, muscle biopsy
examination, and genetic tests [13–15].
Muscle biopsy had an important role in muscular dystrophy diagnosis and still
provides essential information for diagnosis. Although in clinical observations,
family history, muscle biopsy, and biochemical tests such as serum creatine kinase
(CK) are still important tools for muscular dystrophy diagnosis, protein analysis and
genetic study have an increasing importance in accurate establishing a diagnosis.
For several years, until the discovery of other muscle proteins, dystrophin was
the only protein studied to establish a diagnosis of muscular dystrophy. It is also
used today in the differential diagnosis between Duchenne muscular dystrophy
(DMD) and Becker muscular dystrophy (BMD). In the last 10 years, genes involved
in various types of autosomal recessive muscular dystrophy (LGMD) as well as in
congenital muscle dystrophies have been identified [16–18].
Differentiation between recessive muscle dystrophies is much more difficult to
achieve on the basis of clinical criteria because of phenotypic variability [19],
different starting age of onset [20, 21], and a variable progression rate [22].
Identification of protein defect by immunohistochemistry and Western blotting
allows firm and specific diagnosis in a wide variety of muscular dystrophies. How-
ever, while immunohistochemistry is very useful in identifying abnormal expres-
sion of primary protein deficiency, in genetically inherited recessive diseases, it is
less useful for identifying primary defect in dominant diseases.
2.1 Clinical manifestations and symptoms for most common forms of muscular
dystrophy
The patient’s medical history and clinical examination allow the doctor to iden-
tify the signs and the specific symptoms of the diseases. A complete examination
should include evaluation of movement and difficulty controlling movement, gait
abnormalities, muscle strength, and the presence of weakness pattern, and also
identification of the muscle groups affected.
While the most common sign for different types of muscular dystrophy is the
progressive muscle weakness, the other features like age of disease onset, muscle
group affected, and rate of progression are specific for each type of muscular
dystrophy [21, 23].
2.1.1 Dystrophinopathies
Dystrophinopathies are recessive X-linked disorders caused by mutation in dys-
trophin gene [1]. Currently, they are recognized as a spectrum of disease with
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involvement of skeletal and cardiac muscle in different degree [24] and include
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD),
involving mostly skeletal muscles, and DMD-associated dilated cardiomyopathy
(DCM), affecting preferentially the myocardium. The clinical picture in males with
dystrophinopathies ranges from mild to severe. The mild forms consist of high level
of CK in serum and muscle cramps with myoglobinuria. The severe forms include
progressive muscle diseases (Duchenne muscle dystrophy, DMD, Becker muscle
dystrophy, BMD).
2.1.1.1 Duchenne muscular dystrophy (DMD)
In DMD, affected boys are clinically normal at birth. The onset of clinical
features is in early childhood with delayed motor milestones, including delayed
independent walking, with a mean age of walking of 18 months, and difficulties in
standing up from the floor. The most characteristic clinical features of DMD are
general motor delays (42%) and gait problems including persistent toe walking and
flat-footedness (30%) [25]. Patients with DMD have a waddling gait and difficulties
in climbing stairs, running, jumping, and standing up due to proximal weakness
[26]. They rise from a supine position using their arms (Gower maneuver). The
boys have hypertrophic and firm calf muscles [27]. The disease is rapidly progres-
sive, at the age of 12 years, most boys being wheelchair bound [25]. Subsequently,
the function of upper extremity will be lost, and, by the age of 14–15 years, cardio-
myopathy is a common feature [26]; during the teenage years, the patients will
require assisted ventilation [27]. Progressive cardiomyopathy and respiratory com-
plications represent the most common causes of death in patients with DMD.
Typically, the death occurs by 30 years of age, but currently the life expectancy of
these patients has been improved through an improved management of cardiore-
spiratory function [28].
Intellectual disability can be present in up to 27% of boys with DMD, and 44% of
patients have learning disability [28]. Other psychiatric disorders reported in these
patients include attention-deficit hyperactivity disorder (ADHD) (32%), anxiety
(27%), and autism spectrum disorder (15%) [29].
2.1.1.2 Becker muscle dystrophy (BMD)
BMD is a milder form of muscular dystrophy characterized by skeletal muscle
weakness with a later onset and a preservation of the gait for a longer period (age of
40–50 years) [25]. The patients present usually with high serum CK concentration,
calf muscle hypertrophy, muscle cramps, myalgia, or with muscle weakness in the
pelvic and shoulder girdles [26]. Cardiomyopathy is a common complication of
BMD, the mean age of diagnosis being around 14, 6 years [28]. Heart failure
represents the most common cause of death in BMD, at an age of mid-40s [23, 24].
2.1.2 Emery-Dreyfus muscular dystrophy (EDMD)
EDMD is a muscular disorder with different inheritance patterns: X-linked
recessive or autosomal dominant or autosomal recessive [25, 26]. The clinical pic-
ture includes the classical triad: (i) early joint contractures, (ii) slowly progressive
muscle weakness and wasting in humeroperoneal distribution (upper arm, lower
legs), and (iii) cardiac disease (atrial-ventricular conduction anomalies, atrial
arrhythmias) [27]. Usually, the clinical presentation is characterized by Achilles
contractures with toe walking in childhood. Later, arm weakness and elbow con-
tractures develop, associated with biceps or triceps wasting with sparing of deltoid
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muscle (a characteristic pattern called “Popeye arms.” A rigid spine is also present
causing a severe lumbar lordosis [27].
2.1.3 Limb-girdle muscular dystrophies (LGMDs)
LGMDs represent a group of muscular conditions with autosomal dominant or
autosomal recessive inheritance, characterized by a typical pattern of slowly pro-
gressive, proximal weakness which involves shoulder and pelvic girdle muscles
[18, 19]. Different subtypes of LGMDs have been described, with a wide clinical
spectrum affecting various age groups. LGMDs with autosomal dominant inheri-
tance are referred as LGMDs1 and recessive forms, as LGMDs2. LGMDs1 forms
have, generally, a later onset and a milder course compared with autosomal reces-
sive forms [29].
The most affected muscle groups are proximal muscles, namely, the muscles of
the shoulders, upper arms, pelvis, and thighs. The clinical picture can vary among
different subtypes of FSHD, even within the same family [29]. The onset of clinical
features can be at any age and worsen with time. The first symptoms include
abnormal gait (waddling gait, walking on the feet balls) and difficulties in running
and standing up [29]. The muscle weakness slowly progresses, and, in later stage
of the disease, the patients may be wheelchair bound. Other clinical features include
scapular wings, lumbar lordosis, scoliosis, calf muscle hypertrophy and joint
stiffness, that restrict movement of the elbows, hips, knees, and ankles [30]. Car-
diomyopathy was reported in some forms of LGMD, and some patients may present
respiratory difficulties which can vary from mild to severe. In some rare forms of
LGMD, intellectual disability has been reported [31].
2.1.4 Facioscapulohumeral muscular dystrophy (FSHD)
FSHD is a genetic muscular disorder with autosomal dominant inheritance and a
late onset; the disease has a slow progression and a high degree of phenotypic
variability and side-to-side asymmetry [30]. The muscle weakness involves initial,
facial, scapular, and proximal limb muscles (mimetic muscles, serratus anterior,
rhomboid muscles, biceps, and triceps) [21]. The most frequent initial symptom is
the inability to lift arms over shoulder height. Then, the weakness progress to lower
limbs, typically the distal musculature first (tibialis anterior and gastrocnemius),
and later more proximal muscles (quadriceps and hamstrings) and the pelvic girdle
are involved [21]. The abdominal and paraspinal muscles can be affected, causing
an exaggerated lumbar lordosis or camptocormia (bent spine syndrome) [22].
Pectus excavatum is another common feature in FSHD [22]. The risk to become
wheelchair bound is high in the second decade for patients with a more severe
infantile form and after the age of 50 years in about 20% of patients [23].
The respiratory involvement varies from 0 to 13% of patients with FSHD in
different studies [24] and is caused by the loss of core/trunk muscles. It is present
mostly in patients with pelvic girdle weakness who are wheelchair bound or with a
marked paraspinal involvement or kyphoscoliosis. Between 1 and 8% of patients
with FSHD require mechanical ventilation [23].
Cardiac involvement is not common in FSHD. 5–10% of patients can present
supraventricular arrhythmias, mostly asymptomatic [25]; an incomplete right bun-
dle branch block has been found in approximately one-third of patients in one study
[26], with no significant progression.
Some extramuscular manifestations have been described in patients with FSHD,
almost always in the cases with the smallest number of residual D4Z4 units. They
include retinal vascular changes (peripheral telangiectasia); Coats disease, a severe
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retinal vasculopathy characterized by aneurysmal dilatations and exudation, which
can cause retinal detachment or blindness; loss of high-frequency hearing, usually
asymptomatic; hearing loss; and intellectual disability and seizures in infants with
FSHD [32, 33].
A careful, complete, and thorough clinical examination along with laboratory
investigations provides more information necessary for management of patients
with muscular dystrophy, differentiates between the type of muscular dystrophy,
and directs to subsequent analyses.
2.2 Laboratory investigations
When a muscular dystrophy is suspected, blood enzyme test and a variety of
laboratory test can be used for confirmation of clinical diagnosis. The blood serum
samples are used to determine the level of specific enzymes known to have a high
blood serum levels when a dystrophic process is present:
i. Creatine kinase (CK) also known as creatine phosphokinase (CPK), an
intracellular enzyme found with relative predominance in skeletal muscle, is
considered as the most specific and sensitive marker of muscle disease.
Normal reference value of CK ranges between 60 and 174 IU/L into blood
serum [13, 14]. Elevated level of CK could suggest a muscle disease before
symptoms of muscular dystrophy become evident [33, 34]. In early stages of
the muscle disease, CK levels are 20–300 times greater than normal levels and
tend to decrease with the muscle damage [15]. In male DMD patients, the
serum CK level is markedly elevated due to muscle degeneration [17] with less
elevation level noted in BMD patients. Recent studies show that losses of lung
function in DMD patients determine the high level of CK in blood serum [35].
The level of CK has been found higher in other types of MD like limb-girdle
muscular dystrophy (LGMD) [17] and could serve as useful indicator being able to
discriminate between autosomal recessive and dominant types of LGMD, knowing
that CK level recessive types of MD are higher than dominant ones. Also, evaluation
of CK level is a useful screening tool for female DMD carrier.
It is interesting to note that not all cases of MD show a high level of CK. For
example, in Ullrich congenital muscular dystrophy, Emery-Dreifuss muscular
dystrophy, and Bethlem myopathy, the level of CK may be normal or slightly
increased [22].
ii. Aldolase, transaminases (alanine aminotransferase ALT and aspartate
aminotransferase AST), and lactate dehydrogenase (LDH) are other muscle
enzymes also reported with a rise level in blood serum [18] when a muscular
dystrophy is suspected.
Also, from the blood collected on anticoagulant (EDTA), total genomic DNA is
isolated for further genetic tests used to confirm the diagnosis.
Other laboratory tests like electromyography, magnetic resonance imaging (MRI),
combined with muscle biopsy, and genetic tests contribute for toward a diagnosis.
2.3 Muscle biopsy
The assessment of skeletal muscle biopsy is an essential procedure for an accu-
rate diagnosis when a muscle disease is suspected, providing evidence of patholog-
ical changes in muscle and guides for appropriate tests.
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2.3.1 Muscle histopathological analysis
Even though the muscle biopsy is a highly invasive procedure, the data gained
from it has the utmost importance for histopathological diagnosis and is an essential
component in the diagnosis of muscle disorders that could identify the cause of the
disease process and distinguish between different types of muscular dystrophy. The
overall structure of the tissue as well as all specific histological features of dystro-
phic muscle can be observed by hematoxylin and eosin (H&E) staining performed
on frozen sections sampled from the quadriceps or deltoid muscle. Generally, the
features observed in all dystrophic muscle biopsy include fibers’ size variation,
round shape muscle fibers, the presence of atrophy, regenerating and degenerating
fibers, splitting of fibers, proliferation of the connective tissue, and increased num-
ber of internal nuclei. In the end phases of the disease, the fibers are replaced by
adipose tissue [36]. Histopathological changes differ widely in severity among the
types of muscular dystrophy, as well as among allelic variants of the same genotype.
Also, some features are specific for each type of muscular dystrophy. For example,
lobulated fibers are characteristic for LGMD 2A; a high variability in fibers’size is
specific for LGMD 1C, and increased internally nuclei are specific for myotonic
dystrophy; the presence of rimmed vacuoles suggests a myotilinopathy, while prom-
inent vacuoles are found in LGMD [36]. With all signs, none of the specific forms of
muscular dystrophy can be diagnosed just based only on histological analysis.
Also, the muscle biopsy analysis can not only denote the specific genetic cause of
the disease but can also provide clues for further investigation. In combination with
protein analysis, the genetic investigations can provide an accurate diagnosis.
2.3.2 Protein analysis
The study of muscle protein expression is important for diagnosis, for genotype-
phenotype correlations, and to identify possible genetic defect [37–39]. There are
many methods used for the study of muscle protein expression [40], but the most
used are immunostaining methods (immunohistochemistry or similar methods
immunofluorescence and immunoblotting/Western blotting (WB)). Both methods
use labeled antibodies for a specific muscle protein involved in a type of muscular
dystrophy. While the immunohistochemistry/immunofluorescence method is used
to identify the localization and relative abundance of the proteins, in tissue
cryosections, the WB method is useful to detect the total amount of proteins as well
as the normal or reduced size of the proteins in homogenized sample.
2.3.2.1 Immunofluorescence (IF)
In the past, the diagnosis of muscular dystrophy consisted only on clinical
assessment, serum CK levels, and histological investigations of muscle biopsy
[41, 42].
The discovery in 1986 of the first muscle protein involved in a type of muscular
dystrophy, dystrophin [43], has later led to the identification of the dystrophin-
associated protein complex (DAPC) [44] and other additional proteins from the
muscle cytosol (calpain 3, TRIM32) [45], from extracellular matrix (a2-laminin,
collagen VI) from the sarcomere (telethonin, myotilin, titin, nebulin) [46]. Each of
these proteins is involved in a type of muscular dystrophy; so far over 40 types of
muscular dystrophy are known [47].
The development of specific antibodies (Abs) for affected proteins has
improved the diagnosis for these diseases, over time. Now, there are many
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immunohistochemical protocols based on the use of specific antibodies for antigen
localization through antigen-antibody interaction.
IF or fluorescent antibody staining is a helpful routinely technique widely used
to determine the localization of fluorescent-tagged protein and changes in protein
expression on a cryosection (presence, reduced, and absence). It is also used to
investigate muscle architecture.
A large array of antibodies directed against different muscle protein is now
available for current diagnosis and allows the use of these techniques for the diag-
nosis of many muscle disorders (see Table 1).
The use of antibodies directed against muscle protein is useful to gain information
about integrity of muscle complexes, secondary reduction of proteins, and also gene
function by compared normal and affected patients (see Figure 1) [48].
In addition, IF method identifies also the secondary reduction and
overexpression of closely protein levels [49]. For example, utrophin, an autosomal
protein which presents around 80% sequence homology to dystrophin [50, 51] and
localized in normal skeletal muscle at the neuromuscular junction (NMJ) [52], is
overexpressed in dystrophinopathies (see Figure 2) [53, 54]. Mutations in one
sarcoglycan often lead to reduced expression of other sarcoglycans [49], and
reductions of dysferlin (see Figure 3) are observed in other forms of muscular
dystrophy such as calpainopathy, caveolinopathy, and anoctaminopathy [55].
However, IF is not always helpful in diagnosis of all forms of MD. For example,
in LGMD 2A some available antibodies have no immunoreactions on the sections.
Few studies tried to analyze calpain 3 on cryosections but, because of rapid degra-
dation of calpain 3 after harvesting, concluded that immunostaining analysis alone
does not predict the presence of CAPN3 mutations [40]. However, the staining of
other proteins such us dystrophin and sarcoglycans which appear normal on
cryosections by IF could be informative for further analysis.
Also, in dominant forms LGMD1B caused by changes in the LMNA gene which
encode for lamin A/C, immunostaining of cryosection reveals normal expression
even in the presence of a mutation [56].
Antibody Manufacturer Clone Dilution for
cryosection
Dilution for
Western blot
Dystrophin C-terminus Novocstra Dy8/6C5 1:40 1:200
Dystrophin N-terminus Novocstra Dy10/12B2 1:50 1:50
Dystrophin rod domain Novocstra Dy4/6D3 1:20 1:200
Utrophin Novocstra DRP3/20C 1:50 1:200
Calpain 3 Novocstra 2C4 — 1:100
Calpain 3 Novocstra 12A2 — 1:50
Caveolin 3 Santa Cruz A-3 1:50 1:200
Dysferlin Novocstra Ham1/7B6 1:50 1:100
α-Sarcoglycan Novocstra Ad1/20A6 1:50 1:100
β-Sarcoglycan Novocstra BSarc/5B1 1:50 1:100
γ-Sarcoglycan Novocstra 35DAG/21B5 1:50 1:100
Merosin Novocstra Mer3/22B2 1:50 1:50
Table 1.
Details of the most used antibodies in muscular dystrophy diagnosis.
7
Clinical and Molecular Diagnosis in Muscular Dystrophies
DOI: http://dx.doi.org/10.5772/intechopen.85339
It is important to note that to obtain good results in protein evaluation by IF is a
necessary investigation of the integrity of muscle fiber membrane by analysis of
spectrin [54, 57].
All these facts suggest the difficulty of identification with accuracy of a type of
MD based only on histochemical findings and immunofluorescence analysis and
indicate a further investigation of proteins using immunoblot analysis.
Figure 1.
Workflow chart for muscle protein analysis in muscular dystrophy diagnostic process.
Figure 2.
Representative immunofluorescent staining from dystrophin and utrophin in normal human (control) and
DMD and BMD skeletal muscle.
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2.3.2.2 Multiplex Western blotting
Western blot (WB), also called immunoblot, is a semiquantitative method used
to detect specific proteins from cell lysate samples or tissue homogenates using
specific antibodies [58].
Due to higher sensitivity and specificity of the method, WB brings more infor-
mation about proteins that cannot be offered by other immunoassay techniques.
The WB technique is an extremely powerful technique which gives information
about the presence, absence, and size of the proteins, identifying the proteins with
abnormal molecular weight [59, 60].
Usually, this analytical method involved three major processes [61]: (i) separa-
tion of proteins into a SDS-polyacrylamide gel based on their molecular weight; (ii)
protein blotting on a nitrocellulose or polyvinylidene fluoride (PVDF) membrane;
and (iii) visualization of the protein of interest by incubation of membrane with
specific primary antibody and then labeled by secondary antibody conjugate with
an enzyme.
For the preparation of tissue lysates, around 20–80 mg of muscle tissue are
required which may be a significant part of a severely affected muscle. Cooper et al.
[62] reported in 2003 obtaining of the lysate from 16 mg muscle tissue using a single
cryosection (8 μm thick, 10 mm2).
Given the complexity of muscular dystrophies, in recent years, has become
a necessity in the analysis and comparison of the expression of multiple target
proteins involved in a specific pathology.
Also, the technology has improved over time going from the detection of a single
protein to identification of multiple proteins in complex samples using a biphasic
polyacrylamide gel systems and a cocktail of primary antibodies [63]. In our labo-
ratory, polyacrylamide gel system is performed as previously described [63] with
some modifications [64, 65] which permitted separation of the large proteins more
than 200 kDa (e.g., dystrophin) in the top part of the gel while and smaller proteins
under 150 kDa (e.g., calpain 3), in the bottom. The intensity and thickness of the
specific protein bands correspond to the relative abundance of protein of interest.
The amount of target protein is determined by comparing stained band of control
with the patients. Quantification of protein based on densitometry of bands using
ImageJ software provides information about the relative level of protein in muscle.
In DMD patients, the total absence of the bands for dystrophin at 427 kDa is
observed, while BMD patients show a reduced intensity of the bands for dystrophin
(see Figure 4).
Figure 3.
Immunofluorescent staining of dysferlin in normal control muscle and patient with LGMD 2B: (a) expression
of dysferlin from normal patients; (b) reduced expression of dysferlin around some muscle fiber; the presence of
regenerating fiber.
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WB plays an important role in distinguishing between DMD and BMD patients
especially for patients with discordant phenotype (do no respect reading frame rule).
Analysis by WB of calpain 3, protein found to be involved in LGMD 2A, could
show a total or a reduced intensity of bands at 94 kDa. There are cases with LGMD
2A which displayed normal or almost normal bands for calpain 3 compared with
control (see Figure 5).
This fact suggests a poor specificity of WB analysis for this protein [66]. Also,
false-negative results provided by WB can be found in analysis of dysferlin when
this protein is accumulated in the cytoplasm, and deficiency of lamin A/C could not
be identified in all patients with LMNA mutations [67].
However, for these proteins, genetic analyses are required to confirm the exact
diagnosis.
Western blot has the advantage of simultaneous analysis of several proteins which
reduced cost and time for analysis. This method is useful in differential diagnosis of
muscular dystrophies providing information on the relative location of mutation.
2.4 DNA diagnosis methods
The identification and characterization of genetic defect involved in pathology is
often essential both for diagnosis and treatment options as well as in predicting
Figure 4.
Representative Western blotting analysis of muscle homogenates from four patients with muscular dystrophy:
(A) nitrocellulose membrane labeled with antibody against rod domain of dystrophin (NCL-Dys1). (B) Blot
labeled with antibody against C-terminus domain of dystrophin (NCL-Dys2); M-normal control; lane 1-MD
with normal expression of dystrophin; lane 2-BMD; lane 3-DMD, absence of dystrophin band; lane 4-DMD;
lane 5 MD with normal expression of dystrophin. MHC—Corresponding myosin heavy chain bands on the
post-blotted gel, stained with Coomassie blue.
Figure 5.
Calpain 3 band patterns on WB. Representative Western blotting analysis of muscle homogenates from three
patients analyzed with antibody against calpain 3. (a) Nitrocellulose membrane labeled with antibody against
calpain 3 NCL-CALP-2C4 detects bands at 90 and 30 kDa in normal patients. (b) Nitrocellulose membrane
labeled with antibody against calpain 3 NCL-CALP-12A2 detects bands at 90 kDa and two bands at 60 and
30 kDa in normal patients.
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disease prognosis. Additionally, diagnostic accuracy leads to more specific genetic
counseling for families and possible preimplantation prenatal diagnosis.
The great technological advances in molecular assays over the last 20 years have
led to the identification of the molecular genetic cause for many forms of muscular
dystrophy. This advance enabled, thus, the diagnosis of muscular dystrophy to
evolve from the analysis of 20 exons out of 79 exons within hotspot region of DMD
gene by PCR Multiplex [68–70] to multiple gene analysis using next-generation
sequencing (NGS) technique.
Different forms of muscular dystrophy are caused by a variety of mutations that
occurred in many human genes. Mutations that occurred in gene that encode for
proteins from DAPC are responsible for many types of muscular dystrophy. The
most common types of mutations involve large rearrangement (deletion and dupli-
cation) and point mutations. A correct characterization gene mutation for each type
of muscular dystrophy represents the key for genotype-phenotype correlation.
Here, we describe some of the more used molecular techniques in the muscular
dystrophy diagnosis.
2.4.1 Multiplex ligation-dependent probe amplification (MLPA)
Among the different methods used for detection of gene deletions and duplica-
tion, the MLPA assay is the most used due to rapid analysis up to 45 different DNA
fragments in a single PCR amplification with only a single primer pair [71] and low
amounts of genomic DNA. In addition to large deletions and duplications, MLPA
may also identify single exon deletion. This apparent result should be always
checked by an alternative method avoiding false-positive results that can occur in
the presence of a single-nucleotide variation in a gene. This method proves its
usefulness for female’s carrier screening as well as for prenatal testing [72].
Because require equipments that exist in most molecular diagnosis laboratory
(a thermocycler and a capillary electrophoresis), is a very cost-effective method
widely used for both diagnostic and research.
Data analysis can be done by using the free MLPA data analysis software
Coffalyser (MRC-Holland, Amsterdam, the Netherlands) or additional software
such as MLPAinter [73] or GeneMapper v4.0 software [74].
The advantages of MLPA method for diagnosis are (i) low input of DNA
required; (ii) the high specificity and sensitivity, the method being able to distin-
guish sequences differing in only one nucleotide; and (iii) plenty of MLPA kits
available for different genes involved in muscle pathology such as CAPN3, DYSF,
SGCA, SGCB, SGCD, SGCG, and FKRP.
2.4.2 High-resolution melting curve analysis (hrMCA)
High-resolution melting curve analysis (hrMCA) is a highly sensitive molecular
post PCR method introduced in 1997 by Wittwer et al. [75, 76], to identify patho-
genic variants in nucleic acid sequences. The improvement of real-time equipment
regarding highly controlled temperature transitions, data acquisition software to
monitor and analyze the melting, as well as the development of a new functional
class of dyes have made this technology possible.
HRM analysis starts with PCR amplification of the region of interest with spe-
cific primers in the presence of a specialized double-stranded DNA (dsDNA) fluo-
rescent binding dye.
The method is based on the DNA property of dissociating (or melting) from
double-stranded DNA into single-stranded DNA (ssDNA) when exposed to a grad-
ual temperature [77, 78]. The melting process can be real time monitored by
11
Clinical and Molecular Diagnosis in Muscular Dystrophies
DOI: http://dx.doi.org/10.5772/intechopen.85339
measuring the gradually diminishing amount of fluorescence during DNA strand
dissociation. The presence of a mutation in PCR products determines a modification
in the shape of DNA melting curves comparative with melting profile of the wild
type (normal) DNA (see Figure 6).
HR-MCA is a rapid and accurate method for detection of genetic variation in
population. Although HR-MCA is not locus specific, it can become a tool of choice for
point mutations screening after identification of large mutation (deletion and dupli-
cations) by MLPA. The sequencing of the fragments with abnormal melting profile
only, identified by HR-MCA, reduces costs and waiting time per archived results.
2.4.3 Sanger sequencing
All point mutations identified by HR-MCA method need to be confirmed by
sequencing. Sequencing, the most widely used approach for DNA analysis, remains
the “gold standard” for mutation analysis.
The Sanger DNA sequencing method is applied to determine the sequence of a
DNA molecule and to identify the subtle mutations in samples compared with a
reference sequence [79, 80].
Because a lot of muscle proteins associated with different forms of muscular
dystrophy are extremely large, full gene analysis using Sanger sequencing can lead
to higher costs and is time-consuming for analysis. The method finds its usefulness
in the analysis of small gene composed of only few exons in which the frequency of
point mutation is higher. For instance gene that encode for sarcoglycans (e.g.,
SGCA 10 exons, SGCB 6 exons, SGCG 10 exons), for calpain 3 (CAPN3 26 exons),
Figure 6.
Representative high-resolution melting curve analysis which reveals difference in melting shape between wild
type and variant sequence.
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and for dysferlin (DYSF 58 exons) [81] that are associated with LGMDs, is more
suitable for sequencing.
Due to overlapping clinical symptoms and many possible genetic causes for
LGMDs, obtaining a diagnosis is often difficult. Next-generation sequencing becomes
a valuable option for an accurate diagnosis due to ability to analyze a large number
of targets.
In DMD gene (79 exons), a high frequency of point mutations around 35% was
reported [82]. Screening of this huge gene for point mutation is difficult to perform;
therefore it is necessary to select only genomic regions that contain the variants [83].
However, the combined technology MLPA for identification of large deletions
and duplication followed by HR-MCA and sequencing is a robust algorithm for
diagnosis for male muscular dystrophy patients as well as for female carrier and also
for prenatal diagnosis.
2.5 Diagnosis algorithm in the most common forms of MD
2.5.1 Dystrophinopathies
The presence of clinical symptoms in a male child presented in Cap 2.1 along
with increased serum levels of CK, transaminase enzymes or aldolase should trigger
the diagnostic investigation for dystrophinopathies [11]. When DMD or BMD is
suspected, diagnostic recommendation as first investigation is the screening of
DMD gene for deletions and duplications by MLPA. The presence of a mutation in
gene confirms the dystrophinopathies diagnosis.
A large number of research studies highlight the utility of MLPA as detection
methods for DMD gene [84–86] which is the largest gene (2.2 Mb) of the human
genome.
Many different types of mutations that occurred in the DMD gene, encoding for
the cytoskeletal protein, dystrophin, are responsible for both severe disease
Duchenne muscular dystrophy (DMD) and the milder form of the disease Becker
muscular dystrophy (BMD). The difference in disease severity between the two
phenotypes, DMD and BMD, can be explained by the “reading frame rule” pro-
posed by Monaco in 1988 [87]. According to this theory, DMD is caused by muta-
tions which disrupt the reading frame, and no protein will be synthesized, while for
BMD phenotype the mutations do not affect the reading frame leading to the
synthesis of a smaller and semi-functional dystrophin protein.
Previously reported studies have shown that all over the world, deletions of one
or more exons are most common mutation in dystrophinopathies (60–65%),
followed by duplications (5–8%) and point mutations (30–35%) [88]. Around 90%
from all dystrophinopathies cases present worldwide respect reading frame rule.
For the remaining 10% as well as for patients with discordant phenotype, additional
analyses are required for an accurate diagnosis.
Because the mutations have been observed across all exons of the gene with a
higher incidence of mutation in two “hotspots” regions between exons 2–20 and 45–
50 [85, 89], MLPA method proves its utility for the molecular diagnosis of
dystrophinopathies, by simultaneous screening of all 79 exons of DMD gene for
large intragenic rearrangements [90]. All deletion and duplications identified
should be checked for the validity of the reading frame rule on http://www.dmd.nl.
If no deletions and duplication are identified, the DMD gene should be investi-
gated for point mutations [91] by hrMCA followed by sequencing of exons with a
modification of melting curve only. Full characterization of the mutation (type,
size, and position) is important in identification of patients that are eligible for
specific mutation gene therapy [89].
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If a muscle biopsy is the tool of choice as first step in analysis routine, histo-
chemical staining and dystrophin analysis by immunohistochemistry/immunofluo-
rescence and Western blot confirm or not the dystrophinopathies diagnosis based
on the difference in the expression of dystrophin.
Analysis by IF of dystrophin in muscle samples using three monoclonal mouse
antibodies against three domains of protein (C-terminal, rod domain, and N-
terminal) revealed the localization of protein at the sarcolemmal level of skeletal
muscle fibers and displays a normal expression of intensity signal around each
muscle fiber. In DMD patients, dystrophin is absent or severely reduced, while
BMD patients displayed a variable expression of signal for dystrophin. Also, labeling
of dystrophin on sections plays a critical role in identification process of the DMD
female carriers which display a mosaic pattern of dystrophin expression.
Western blot as additional method confirms the diagnostic.
It’s important to note that the protein result should be confirmed by genetic
analysis.
2.5.2 Limb-girdle muscular dystrophies
Limb-girdle muscular dystrophies (LGMD) are a highly clinically and geneti-
cally heterogeneous group of muscle disorders that affect in both males’ and
females’ voluntary muscles of the pelvic and shoulder areas [92].
Major advances in last decades, both in neuromuscular disorders field and diag-
nostic assays, made that many genes associated with LGMDs to be found such us:
CAPN3 (encode for calpain 3), DYSF (encode for dysferlin), FKRP (encode for
fukutin), SGCA, SGCB, SGCG, and SGCD (that encode for the α-, β-, γ-, and δ-
sarcoglycan), and more than 30 forms of LGMDs to be characterized [11, 37].
However, a significant number of patients clinically diagnosed with LGMDs remain
molecularly uncharacterized [93].
Based on their inheritance pattern were classified in dominant (type 1 LGMD)
and recessive forms (type 2 LGMD) [94].
Giving the complexity of the clinical symptoms and different genes involved, a
diagnosis algorithm for these pathologies is still waiting, but comprehensive guide-
lines for identifying these disorders have been published. The initial evaluation of a
patient involves clinical examination, followed by laboratory test such as serum
creatine kinase measurements, genetic tests, and muscle biopsy analysis. CK level
can vary from lower level in dominantly inherited LGMD forms to very high level
in recessively inherited forms [95].
All these diagnostic approaches should be sufficient to accurately predict the
correct form of LGMDs. In the last years, the increasing use of next-generation
sequencing technology for simultaneous analysis of known LGMD-related genes
improved diagnostic rate and offered opportunity to identified new disease-related
genes [96]. However, this technology is extremely expensive and is not yet available
in all the molecular diagnostic laboratories.
If the clinical features, laboratory tests, and other investigations such as electro-
myography, magnetic resonance, or ultrasound imaging suggest a LGMD, muscle
biopsy [97] may be considered an appropriate test to start the investigation.
Routine histochemical stains will display variable degree of typically dystrophic
feature characteristic for LGMD: variation in fiber size, degeneration and regenera-
tion fiber, presence of internal nuclei, and increased endomysial fibrosis [37, 40].
Disease prediction based on clinical and histochemical tests alone is difficult to
achieve, so immunohistochemical stains (IHC or IF) of specific muscle proteins
involved in LGMDs (calpain 3, dysferlin, caveolin3, the sarcoglycans, myotilin,
lamin A/C, etc.) provides useful information about the presence, absence and
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changes in protein expression. Muscle biopsy is not always informative taken into
account the secondary protein reduction in addition to the primary protein defi-
ciency but can guide to targeted genetic tests. Although genetic testing can be
expensive, it will identify the exact defect of the disease. Being composed only few
exons and considering that LGMDs could have many possible genetic causes, the
sequencing of genes is the most suitable method of choices for diagnosis.
Autosomal dominant LGMDs’ form is quiet rare in population. Recessive forms
are more common and studied. The most commonly recessive form of LGMDs and
the most studied are LGMD 2A (calpainopathy) and LGMD 2B (dysferlinopathy).
2.5.2.1 Limb-girdle muscular dystrophy 2A (LGMD2A)
LGMD 2A is the most common form of limb-girdle muscular dystrophy
accounting for about 30% of all LGMDs, caused by mutation in CAPN3 gene which
encodes for calcium sensitive dependent protease-calpain 3 protein.
Besides the clinical manifestation and laboratory investigation of serum enzymes
presented above, for characterization of this condition, searching for mutations in
CAPN3 gene in correlation with protein calpain 3 investigations by Western blot
represents the “gold standard” in LGMD2A. The identification of the mutations in
CAPN3 gene is most often difficult due to many genetic variations which appear in
this gene and the position they have in the gene.
The improvement of next-generation sequencing technology (NGS), which
screens genomic DNA for a large number of genes involved in neuromuscular
disease, makes LGMD diagnosis easier to achieve. However, in most laboratories,
the diagnosis starts with screening for mutation by direct Sanger sequencing analy-
sis of the 24 exons of the CAPN3 gene. With this method more than 95% cases are
diagnosed. Even if this analysis is successful, in most cases, there are not always
identify large deletions and duplications as well as intronic splice mutations [98].
This fact shows importance of screening for large genomic rearrangements by
MLPA, the most cost-effective techniques. Sanger sequencing combined with
MLPA leads to an increase in the mutation detection rate and remains one of the
most valuable diagnostic tools. Therefore, when DNA analysis is not conclusive, a
muscle biopsy is required for protein analyses.
Until this moment, only few studies reported the success of immunohistochem-
ical technique application for the diagnosis of LGMD using calp3d/12A2 and
calp2C4 antibodies [40, 99] and demonstrated the localization of calpain 3 in
myofibrils and myonuclei.
Nowadays, it is widely accepted that WB, even if it does not have a high
accuracy, is the most suitable method for calpain 3 analysis.
In general, for analysis, two antibodies which produce characteristic patterns of
bands are used: NCL-CALP-2C4 directed against exon 1 which recognizes the full-
sized protein at 94 kDa and additional band at 30 kDa and NCL-CALP-12A2 against
exon 8 that recognizes also to the full-sized protein at 94 kDa and additionally bands
doublet at 60 and 54 kDa. An example of normal calpain on blot is shown in
Figure 5.
Identification and interpretation of the pattern of bands obtained on WB by
using the two antibodies for calpain 3 provide useful information about protein
expression in muscle. Generally, it is widely accepted that the complete absence of
all specific calpain 3 bands on blot is specific for LGMD2A diagnosis and is due to a
primary defect in CAPN3 [100]. The presence of a normal amount of calpain-3
protein on blot does not exclude the LGMD 2A diagnosis. The normal amount of
calpain-3 protein on blot in patients with LGMD 2A was reported [101] by several
studies. The possible explanation of normal expression but functionally inactive
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protein is due to a functional enzyme defect that impairs the autolytic or proteolytic
activity of protein without elimination of protein from the muscle [102, 103].
The reduction is more difficult to interpret because calpain-3 appears to reduce
in amount as secondary effect in other forms of muscular dystrophies such as
dysferlinopathies [40] and titinopathies [81, 92].
Even if muscle calpain-3 results on blot should always be confirmed by mutation
analysis, Western blot remains one of the most valuable diagnostic tools in LGMDs
allowing for the simultaneous analysis of multiple proteins, identifying both the
primary defect and the secondary reductions.
3. Summary and future directions
For most forms of muscular dystrophy, the diagnosis is still challenging, and a
multidisciplinary approach is always required. Only a good knowledge of protein
and gene involved in pathology can provide the correct diagnosis and is essential for
therapeutic interventions. New genetic therapies under development like exon
skipping which tried to restore the reading frame with antisense oligonucleotides
and to transform severe DMD phenotype in a less severe phenotype require a good
characterization of the mutation.
When clinical symptoms are combined with protein analysis by immunofluo-
rescence and Western blot, and with high-throughput DNA molecular technique
such us MLPA, hrMCA, and sequencing, the diagnostic capabilities greatly improve
and can provide an accurate diagnosis.
A defined genetic diagnosis is important for an appropriate treatment and
genetic counseling as well as inclusion of patients in further clinical trials.
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